Phathom Pharmaceuticals (PHAT) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Shattuck Labs (STTK) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, gaining 130.8% versus a loss of 37.2%. Over five years, STTK leads with a -70.7% price change compared with -79.1% for PHAT. Shattuck Labs is the larger company by market cap ($567.6 million vs $550.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHAT | STTK |
|---|---|---|
| Share price | $6.81 | $5.66 |
| Market cap | $550.94M | $567.55M |
| 1-day change | +0.44% | -3.50% |
| YTD return | -58.95% | +54.93% |
| 1-year return | -37.18% | +130.82% |
| 5-year return | -79.05% | -70.74% |
| Forward P/E | 6.33 | — |
| EPS (TTM) | $-1.26 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.31 | $8.33 |
| 52-week low | $6.52 | $1.70 |
| Distance from 52-week high | -62.81% | -32.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +200.29% | +169.14% |
| Average volume | 1.39M | 1.20M |
| Shares outstanding | 80.90M | 100.36M |
| Employees | 371 | 40 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed PHAT by 168.0 percentage points over the past year.
- The two companies sit in different sectors: Phathom Pharmaceuticals in Health Care and Shattuck Labs in Healthcare.
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Healthcare · Biotechnology · 40 employees
PHAT vs STTK FAQ
Which is bigger, Phathom Pharmaceuticals or Shattuck Labs?
Shattuck Labs (STTK) is larger, with a market capitalization of $567.55M compared with $550.94M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, PHAT or STTK?
STTK returned +130.82% over the past 12 months, compared with -37.18% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Phathom Pharmaceuticals and Shattuck Labs in the same industry?
No. Phathom Pharmaceuticals is in the Health Care sector, while Shattuck Labs is in Healthcare.